Advances In Inflammatory Bowel Diseases

Ulcerative colitis and Crohn's disease remain a great therapeutic challenge to the medical community. In recent years knowledge about the pathogenesis of these diseases has progressed rapidly but the cause of the diseases remains completely unknown. It has become clear that dysregulation of the mucosal immune system is the basis for the chronic evolution of the diseases in a genetically susceptible population. Exciting new therapeutic approaches have been attempted in the last couple of years and cytokine and anti-cytokine treatments in particular seem very promising, especially in intractable disease. The format of the Falk Symposium 106 on `Advances in Inflammatory Bowel Diseases', held in Brussels, Belgium, June 18-20, 1998, was somewhat innovative as each session attempted to link the new insights into pathogenetic mechanisms with new therapeutic approaches, resulting in optimal information transfer. The classic therapeutic schemes were updated with a special focus on step-wise build-up of therapy.

Falk Symposium No. 82, held in Halle, Germany, November 1994, focuses on the advances made in understanding the aetiology and pathogenesis of inflammatory bowel disease (IBD). Sections of this book, the Proceedings of the conference, are devoted to extraintestinal manifestations, cancer development, IBD in the context of pregnancy, and the assessment of disease activity, prognosis and quality of life. The second half of the book is devoted to the discussion of standards and new developments in diagnosis, conservative management and surgery. Audience: All clinicians and basic scientists working in the field of IBD.

Inflammatory Bowel Diseases: Advances in Research and Treatment: 2011 Edition is a ScholarlyEditions™ eBook that delivers timely, authoritative, and comprehensive information about Inflammatory Bowel Diseases. The editors have built Inflammatory Bowel Diseases: Advances in Research and Treatment: 2011 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Inflammatory Bowel Diseases in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Inflammatory Bowel Diseases: Advances in Research and Treatment: 2011 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.

Inflammatory Bowel Diseases—Advances in Research and Treatment: 2012 Edition is a ScholarlyEditions™ eBook that delivers timely, authoritative, and comprehensive information about Inflammatory Bowel Diseases. The editors have built Inflammatory Bowel Diseases—Advances in Research and Treatment: 2012 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Inflammatory Bowel Diseases in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Inflammatory Bowel Diseases—Advances in Research and Treatment: 2012 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.

Inflammatory Bowel Diseases—Advances in Research and Treatment: 2013 Edition is a ScholarlyEditions™ book that delivers timely, authoritative, and comprehensive information about Crohn’s Disease. The editors have built Inflammatory Bowel Diseases—Advances in Research and Treatment: 2013 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Crohn’s Disease in this book to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Inflammatory Bowel Diseases—Advances in Research and Treatment: 2013 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.

As in the first edition of Inflammatory Bowel Diseases this new edition continues to provide readers with a concise, yet in-depth review of many of the important areas in the history, epidemiology, pathogenesis, diagnosis, and treatment of the inflammatory bowel diseases (ulcerative colitis and Crohn's disease), as well as associated issues: extraintestinal manifestations, ostomy care, women's issues, economics, etc. This Second Edition provides the reders with up-to-date, state-of-the art approaches to these disease states, with expansion into the newer topics that have emerged in the past few years which include the expansion of biological agents for treatment, new studies in the epidemiology of IBD, the changing economics of IBD, breakthroughs in new endoscopic evaluations, major advances in novel radiographic techniques, the detection of colorectal cancer in patients with IBD and new findings in the genetics of IBD. New Trend / Developments (* These all emerged since our last edition) The most critical trend that has arisen over the past few years has been the introduction and expansion of biological agents in the treatment of inflammatory diseases worldwide. While only one agent, infliximab (Remicade), existed at the time of publication of my first edition, there have been multiple other agents either approved or pending approval for the treatments of these diseases, or in the upper-stages of development. The impact is not only upon the patients, but also on the health-care providers, policy makers, researchers, biotech and pharmacompanies, and the business community. Major changes worldwide in the epidemiology of IBD has spurred new studies in the demographics of who is getting these diseases and why. Previously characterized as diseases primarily affected Caucasians in industrialized countries, there has been an explosion of growth amongst the African American and Hispanic populations in the United States, and well as in pockets of these and other ethnic groups worldwide. The economics of IBD has been changing greatly, given the issues raised above, as well as major changes in the United States Medicare program, and other insurance changes. The growing proportion of the GNP that healthcare costs are consuming in the US and worldwide has shifted attention to decreasing utilization of health care services, and other cost-savings measures. Again, up to this point this has been an exclusive part of our IBD book. New findings in the genetics of IBD have been recently published. Our first edition had the finding of the first Crohn’s disease gene inserted just before going to press; so much has been published about the phenotypes and other genotypes that have emerged. Breakthroughs in new endoscopic evaluations of the bowel (ie. Capsule endoscopy, double-balloon enteroscopy, endoscopic ultrasound) and their use in the inflammatory bowel diseases will be a key highlight of this new book. Major advances in novel radiographic techniques employed in patients with inflammatory bowel disease (ie. CT enterography, MR enterography, advanced ultrasounds, etc.) will also an important component of our work. There have been numerous areas related to the development and detection of colorectal cancer in patients with IBD that have emerged in the past few years. Techniques of better detection (ie. Narrow band imaging; special mucosal staining; endoscopic histological evaluations) as well as research in the putative role of mesalamine and other agents for colorectal cancer prevention are all hot topics that will attract much interest from a variety of interest groups I described above. Identification of additional disease states that probably belong in the IBD family, such as microscopic colitis (including lymphocytic colitis), and collagenous colitis add to the diseases that will be discussed in this new edition.

This comprehensive New Edition describes all of the latest scientific and clinical advances in the field of inflammatory bowel disease (IBD). A new editorial team-joined by a superb group of international authorities-examine every aspect of IBD-including etiology and pathogenesis, diagnosis and evaluation, medical and surgical therapy, and more. A wealth of expanded coverage, additional international contributors, extensive updating throughout, and numerous diagnostic and therapeutic algorithms make this an essential resource. Emphasizes evidence-based medicine in the section on medical therapy. Features a detailed description of inflammatory and immunologic pathways, allowing the reader to fully understand the contributing influences to the inflammation of IBD. Presents separate chapters on molecular genetics and clinical genetics for more in-depth coverage of each aspect of inflammatory bowel disease genetics. Provides a comprehensive review of IBD through abundant, high-quality endoscopic, radiographic, and histologic photographs-placing the various diagnostic modalities in perspective. Offers extensive coverage of postoperative recurrence of Crohn's disease · pouchitis · microscopic colitis · perianal disease · and osteoporosis. Includes up-to-the-minute guidance (including many 2003 references). Features a new editorial team, joined by numerous new contributors who provide fresh, global perspectives. Includes nine new chapters. Offers expanded coverage throughout, and through revisions of all pre-existing chapters. With over 75 additional contributing experts.

Now published in two volumes to accommodate new chapters on the many advances in understanding and treatment options, this set of volumes represents the definitive reference on inflammatory bowel disease, a spectrum of diseases that is receiving increasing attention as our understanding of the etiological factors increases and diagnostic tools are refined. Basic research accelerated at the beginning of this decade and is now yielding new, more targeted treatments than were available just a few years ago. Volume 1 is on IBD and Ulcerative Colitis, and Volume 2 is on IBD and Crohn's Disease. All areas that were covered in the 2nd edition have been expanded and updated. New sections include the rapidly expanding knowledge of genetics and the role of the intestinal flora and environmental factors in etiology and pathogenesis. Among the 168 chapters, there are 20 on biologic therapies and 30 on surgical management. The consultant/authors clearly state their approach to important issues, such as the duration of immunomodulator and of anti-TNF-a use and the options for managing isolated low-grade dysplasia. A strong focus on the individual patient is woven throughout both volumes, including the benefits and risks of potentially life-altering therapies and surgeries. Entire sections detail concerns about the well-being of each person. This book provides information for health professionals who help both pediatric and adult patients navigate through the lifelong shadow of a chronic, probably genetically determined ordeal.